✦ LIBER ✦

TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer

✍ Scribed by Danielle Meijer; Maurice P. H. M. Jansen; Maxime P. Look; Kirsten Ruigrok-Ritstier; Iris L. van Staveren; Anieta M. Sieuwerts; Ton van Agthoven; John A. Foekens; Lambert C. J. Dorssers; Els M. J. J. Berns

Publisher: Springer US
Year: 2008
Tongue: English
Weight: 330 KB
Volume: 113
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-008-9934-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical pharmacology of tamoxifen in pa

Clinical pharmacology of tamoxifen in patients with breast cancer: Correlation with clinical data

✍ Carol Fabian; Larry Sternson; Moustafa El-serafi; Lyn Cain; Erwin Hearne 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 643 KB

Lack of any association between function

Lack of any association between functionally significantCYP2D6polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment

✍ In Hae Park; Jungsil Ro; Sohee Park; Hyeong-Seok Lim; Keun Seok Lee; Han Sung Ka 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 333 KB

Clinicopathologic factors of the recurre

Clinicopathologic factors of the recurrent tumor predict outcome in patients with ipsilateral breast tumor recurrence

✍ Valerie Panet-Raymond; Pauline T. Truong; Cheryl Alexander; Mary Lesperance; Rac 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 223 KB 👁 1 views

Progesterone receptor is a significant f

Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients

✍ Shuzhen Liu; Stephen K. Chia; Erika Mehl; Samuel Leung; Ashish Rajput; Maggie C. 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 415 KB

Clinical recognition and management of d

Clinical recognition and management of depression in node negative breast cancer patients treated with tamoxifen

✍ Cynthia K. Cathcart; Stephen E. Jones; C. Sue Pumroy; George N. Peters; Sally M. 📂 Article 📅 1993 🏛 Springer US 🌐 English ⚖ 387 KB

High levels of tissue inhibitor of metal

High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer

✍ Kevin McCarthy; Teresa Maguire; Gerald McGreal; Enda McDermott; Niall O'Higgins; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 67 KB 👁 2 views

Studies from model systems suggest that matrix metalloproteinases (MMPs) are causally involved in tumor progression while tissue inhibitors of MMPs (TIMPs) prevent this progression. Here, we show that concentrations of TIMP-1 are significantly higher in breast carcinomas than in fibroadenomas. In pr